Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.41
  • Today's Change0.22 / 3.55%
  • Shares traded103.42k
  • 1 Year change+137.41%
  • Beta3.4695
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Mesoblast Ltd (ADR) share price to rise to 11.00 in the next year from the last price of 6.41.
High71.6%11.00
Med71.6%11.00
Low71.6%11.00

Earnings history & estimates in USD

On Aug 30, 2023, losses of -0.28 per share. This result exceeded the -0.31 consensus loss of the 4 analysts covering the company
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate+2.51%
Mesoblast Ltd (ADR) reported annual 2024 losses of -0.89 per share on Aug 28, 2024.
Average growth rate+11.09%
More ▼

Revenue history & estimates in USD

of 2.14m. This missed the 2.38m consensus estimate of the 5 analysts following the company.
Average growth rate+2.67%
Mesoblast Ltd (ADR) had revenues for the full year 2024 of 5.90m. This was 21.32% below the prior year's results.
Average growth rate-21.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.